



OPEN ACCESS

EDITED AND REVIEWED BY
Carlos Alves,
University of Coimbra, Portugal

*CORRESPONDENCE
Martijn J. Schuemie,
schuemie@ohdsi.org

SPECIALTY SECTION
This article was submitted to
Pharmacoepidemiology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 03 November 2022
ACCEPTED 04 November 2022
PUBLISHED 24 November 2022

CITATION
Schuemie MJ, Arshad F, Pratt N,
Nyberg F, Alshammari TM, Hripcsak G,
Ryan P, Prieto-Alhambra D, Lai LYH, Li X,
Fortin S, Minty E and Suchard MA (2022),
Corrigendum: Vaccine safety
surveillance using routinely collected
healthcare data—An empirical
evaluation of epidemiological designs.
Front. Pharmacol. 13:1088973.
doi: 10.3389/fphar.2022.1088973

COPYRIGHT
© 2022 Schuemie, Arshad, Pratt,
Nyberg, Alshammari, Hripcsak, Ryan,
Prieto-Alhambra, Lai, Li, Fortin, Minty
and Suchard. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Vaccine safety surveillance using routinely collected healthcare data—An empirical evaluation of epidemiological designs

Martijn J. Schuemie^{1,2,3*}, Faaizah Arshad^{1,3}, Nicole Pratt⁴,
Fredrik Nyberg⁵, Thamir M Alshammari⁶, George Hripcsak^{1,7},
Patrick Ryan^{1,2,7}, Daniel Prieto-Alhambra^{8,9}, Lana Y. H. Lai¹⁰,
Xintong Li¹¹, Stephen Fortin², Evan Minty¹⁰ and
Marc A. Suchard^{1,3,12}

¹Observational Health Data Sciences and Informatics, New York, NY, United States, ²Observational Health Data Analytics, Janssen R&D, Titusville, NJ, United States, ³Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, United States, ⁴Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia, ⁵School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia, ⁷Department of Biomedical Informatics, Columbia University, New York, NY, United States, ⁸Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, United Kingdom, ⁹Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands, ¹⁰O'Brien Institute for Public Health, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Medical Sciences, University of Manchester, Manchester, United Kingdom, ¹²Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, United States

KEYWORDS

vaccine safety, routinely collected data, adverse event, surveillance, methods

A Corrigendum on Vaccine safety surveillance using routinely collected healthcare data—An empirical evaluation of epidemiological designs

by Schuemie MJ, Arshad F, Pratt N, Nyberg F, Alshammari TM, Hripcsak G, Ryan P, Prieto-Alhambra D, Lai LYH, Li X, Fortin S, Minty E and Suchard MA (2022). *Front. Pharmacol.* 13: 893484. doi: 10.3389/fphar.2022.893484

In the published article, there was an error in [Figure 4](#) and [Figure 5](#) as published. After publication, the authors found that the positive control imputation multiplication was accidentally applied twice, meaning the intended multiplication of 1.25, 2, and 4 actually were $1.25^2 = 1.5625$, $2^2 = 4$, and $4^2 = 16$, respectively. This means the type 2 error in [Figure 4](#) and the time to 50% sensitivity in [Figure 5](#) were underestimated. The corrected [Figure 4](#) and [Figure 5](#) appear below.

In the published article the same error was present in the [Supplementary Material](#). This means the type 2 error and the time to 50% sensitivity were underestimated. The correct [Supplementary Data Sheet S1](#) can be found in the [Supplementary Materials](#).




FIGURE 5
Time to 50% sensitivity after calibration. For each method variation and vaccine group, the number of months of data needed to achieve 50% sensitivity based on the calibrated MaxSPRT in the Optum EHR database are shown, stratified by true effect size of the positive controls. HPV = Human papillomavirus, PS = Propensity Score, SCCS = Self-Controlled Case Series, SCRI = Self-Controlled Risk Interval, TaR = Time-at-Risk.




FIGURE 4
Type 1 and 2 error before and after empirical calibration. For each method variation and vaccine group, the type 1 and 2 error before and after empirical calibration in the Optum EHR database are shown. The x-axis indicates the type 1 error (higher values to the left) and type 2 error (higher values to the right), based on the (calibrated) one-sided *p*-value. The dashed line indicates nominal type 1 error of 5%. HPV = Human papillomavirus, PS = Propensity Score, SCCS = Self-Controlled Case Series, SCRI = Self-Controlled Risk Interval, TaR = Time-at-Risk.

The authors apologize for these errors and state that they does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the

reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fphar.2022.1088973/full#supplementary-material>